Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945539 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964306 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1582511 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9964305 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL705500 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL859968 | 1.00 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25400489 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16572007 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12170354 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17972429 | 0.89 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230105319-A1 | PRODRUG INCORPORATED sgRNA SYNTHESIS | CRISPR THERAPEUTICS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| EP-2691118-B1 | PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS | SCHAEFER KONSTANZE (DE) | 2019-05-01 | — | — | EP | disclosed |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2019-03-21 | — | — | US | disclosed |
| US-9988415-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | SLC28A1 479/4885SLC28A2 505/4885SLC29A1 704/4885 |
| US-20190085013-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | SLC28A1 17/4885SLC28A2 23/4885SLC29A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.